Medicare Panel To Review Compendia To Guide Off-Label Cancer Drug Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
The compendia are used by CMS carriers to make local coverage determinations for off-label oncology treatment.
You may also be interested in...
Part D Enrollment Deadline Approaches With Fewer Than 6 Mil. Eligibles Still Unenrolled
The federal government is on the verge of ensuring that 90% of Medicare-eligible people receive prescription drug coverage, HHS Secretary Leavitt said.
GSK Takes Cue From Schering Patient Assistance Program, Seeks Opinion From OIG
HHS Office of Inspector General will decide whether GlaxoSmithKline can donate medicines to Part D-enrolled patients.
CAP Median Bid Prices, Physician Indifference Likely Contributed To Vendors Spurning Contracts
BioScrip will be the only provider of Medicare Part B-covered drugs through the competitive acquisition program for three years.